Company Profile

Mycosynthetix Inc
Profile last edited on: 11/3/18      CAGE: 47QV9      UEI: JEPXCJLSMLS3

Business Identifier: Unique fungal metabolites for discovery of novel medicines and agrochemicals
Year Founded
2001
First Award
2004
Latest Award
2016
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

505 Meadowland Drive Suite 103
Hillsborough, NC 27278
   (919) 245-0600
   info@mycosynthetix.com
   www.mycosynthetix.com
Location: Single
Congr. District: 04
County: Orange

Public Profile

Mycosynthetix library containing over fifty five thousand fungal isolates, representing in the order of five hundred million genes and their products, is a unique resource capable of providing hundreds of thousands of novel biologically active secondary metabolites and enzymes. The firm's unique collection and the extensive Mycosynthetix database together with experience in cultivating these organisms makes us an ideal discovery partner for companies interested in accessing the chemical diversity of fungal metabolites. Collaborators benefit from many years of research with ollection by: access to one of the largest privately held fungal collections; libraries of fungal metabolites including novel, patentable compounds; optimized production of lead compounds; biotransformation of lead compounds; customized fungus isolation program; advisory services in the natural products and discovery areas In addition to our service role in supporting natural products discovery groups, Mycosynthetix has an in-house program addressing neglected diseases including tuberculosis and malaria,

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2016 1 NIH $241,400
Project Title: Fungal Metabolites Fuel Drug Discovery for Pathogenic Free-Living Amoebae
2014 1 NIH $225,000
Project Title: Fungal Metabolites as Novel Anthelmintics Against Soil-Transmitted Helminthes.
2012 1 USDA $100,000
Project Title: Production of the Organic Herbicide Mevalocidin by Fungi
2009 1 NIH $135,992
Project Title: New Tuberculosis Antibiotics From Filamentous Fungi
2004 1 NIH $100,000
Project Title: Novel Broad/Narrow-Spectrum Antibiotics Against Bacteria

Key People / Management

  William McCulloch

  Cedric Pearce -- Chief Executive Officer; Chief Scientific Officer

Company News

There are no news available.